The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer
NCT ID: NCT01942759
Last Updated: 2014-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
43 participants
OBSERVATIONAL
2013-09-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET
NCT00904410
FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer
NCT06877949
Positron Emission Tomography in Patients With Breast Cancer
NCT00001385
Comparison of Diagnostic Performance of an Algorithm and a High Definition Classical Iterative Algorithm Positron Emission Tomography (PET) to 18Fluoro-deoxy-glucose (18FDG) in the Evaluation of Axillary Lymph Node Invasion of Breast Tumors
NCT01436591
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
NCT03846167
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Histologic grade
According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
No interventions assigned to this group
Axillary metastasis
Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
No interventions assigned to this group
Modified Nottingham prognostic index
NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)
The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (\>5.4) prognostic groups
No interventions assigned to this group
Oestrogen receptor status
Negative Positive
No interventions assigned to this group
Progesterone receptor status
Negative Positive
No interventions assigned to this group
HER-2 neu status
Negative Positive
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* before breast surgery
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bagcilar Training and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aynur Ozen
Aynur Ozen
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AYNUR OZEN, MD
Role: STUDY_CHAIR
Bagcilar Training & Research Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bagcilar Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BC-PET-MR-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.